Hi all
Thought this 14 minute interview on 27 April 2017 may be a good outline of how MSCs work and summary of the recent progress made with our phase 3 programs.
brief notes:
-Potential CHF breakthrough or RAT designation after NIH read out end of this year
-Talks about Japan aGVHD & Phase 3 trial in US, read out end of 2017/early 2018
-Disc program; single administration shows durable effects
-MNK hospital based w $3bn in revenue, committed to regenerative medicine. MNK need to diversify their revenue, so far interaction is positive.
-RA; Interviewer believes this is game-changing data.
- Financing: Non-dilutive funding mentioned.
Hi all Thought this 14 minute interview on 27 April 2017 may be...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
0.010(0.66%) |
Mkt cap ! $1.741B | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.54 | $1.48 | $5.605M | 3.713M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 55197 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.53 | 29782 | 3 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |